Amphipathic Nanodiamond Supraparticles for Anticancer Drug Loading and Delivery
Source abstract
Abstract
Nanodiamonds (NDs) have been attracting considerable attention due to their outstanding chemical, physical, and physiological properties. Additional functionalization of NDs can be carried out by the self-assembly technique. This study reports a straightforward chemical route for self-assembled supraparticles (SPs) based on ND (ND-SPs) using alkyl carboxylic acids with different aliphatic alkyl chain lengths by carbodiimide chemistry and sonication. Poly(ethylene glycol) (PEG)-modified ND-SPs are synthesized successfully for effective nanodrug formulations with the hydrophobic anticancer drug paclitaxel (PTX). The properties of these ND-SP nanomedicines are investigated thoroughly by complementary analytical, spectroscopic, and microscopic techniques. This simple methodology permitted the application of PEG-modified ND-SP-encapsulating PTX as a potent drug carrier, achieving greater efficacy than commercial Abraxane. Results revealed that the morphology, particle size, and water dispersibility of the prepared ND-SP nanoclusters affect the drug efficacy. These PEG-modified ND-SP nanoclusters serve as novel nanomedicine for a passive drug delivery system as well as anticancer chemotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Diamond and Carbon-based Materials Research · Nanoparticle-Based Drug Delivery · Carbon Nanotubes in Composites
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Materials and Chemistry, Nanomaterials Research Institute (NMRI), National Institute of Advanced Industrial Science and Technology (AIST), Central 5, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8565, Japan
Corporate Research Center, R&D Headquarters, Daicel Corporation, 1239, Shinzaike, Aboshi-ku, Himeji, Hyogo 671-1283, Japan
Advanced Materials Planning, R&D Headquarters, Daicel Corporation, 2-19-1 Konan, Minato-ku, Tokyo 108-8230, Japan
Funding
Japan Society for the Promotion of Science · Daicel Corporation
References (29)
Show source-provided references
1. 10.1007/s11095-016-1958-510.1007/s11095-016-1958-5 ↗
2. 10.1002/wnan.141610.1002/wnan.1416 ↗
3. Ventola C. L. · Pharm. Ther. · 2012 · 37 · 512
4. 10.1208/s12248-016-9970-610.1208/s12248-016-9970-6 ↗
5. 10.1208/s12248-016-9961-710.1208/s12248-016-9961-7 ↗
6. Malic E. · 201310.1002/9783527658749 ↗
7. Ro C. N. R. · 2013
8. 10.2217/nnm.13.14010.2217/nnm.13.140 ↗
9. Arnault J. C. · 2017
10. 10.1021/acsnano.6b0453510.1021/acsnano.6b04535 ↗
11. 10.1039/c1sc00360g10.1039/c1sc00360g ↗
12. 10.1126/science.114317610.1126/science.1143176 ↗
13. 10.1021/nl071245d10.1021/nl071245d ↗
14. 10.1021/nn900274310.1021/nn9002743 ↗
15. 10.1039/C8NR00641E10.1039/C8NR00641E ↗
16. 10.1289/ehp.100234610.1289/ehp.1002346 ↗
17. 10.1016/j.envres.2018.10.02310.1016/j.envres.2018.10.023 ↗
18. 10.1007/s10573-005-0072-510.1007/s10573-005-0072-5 ↗
19. 10.3103/S106345760804002310.3103/S1063457608040023 ↗
20. 10.3103/S106345761303003910.3103/S1063457613030039 ↗
21. 10.1016/0019-0578(93)90075-810.1016/0019-0578(93)90075-8 ↗
22. 10.1039/b904302k10.1039/b904302k ↗
23. 10.1126/sciadv.150043910.1126/sciadv.1500439 ↗
24. 10.1016/j.jconrel.2017.05.03310.1016/j.jconrel.2017.05.033 ↗
25. 10.1016/j.actbio.2016.07.01510.1016/j.actbio.2016.07.015 ↗
26. 10.1016/j.addr.2015.09.01210.1016/j.addr.2015.09.012 ↗
27. 10.1016/j.cis.2018.11.00410.1016/j.cis.2018.11.004 ↗
28. 10.1007/s40273-018-0646-110.1007/s40273-018-0646-1 ↗
29. 10.1038/cr.2010.1910.1038/cr.2010.19 ↗